What is a pharmaceutical royalty and how do royalty companies work?

When a pharmaceutical company licenses a drug patent or technology to another company, the licensor often receives royalties — a percentage of the commercial product's net sales; royalties are ongoing passive income tied to the drug's commercial performance. Innoviva's origin: Innoviva (formerly Theravance) co-developed the Ellipta respiratory technology with GlaxoSmithKline; after GSK obtained commercial rights and began selling Ellipta products globally (Breo Ellipta approved 2013), Innoviva retained royalty rights on worldwide net product sales. Royalty model advantages: no operational complexity — Innoviva doesn't need a manufacturing facility, clinical development team, or commercial sales force; income is passive; low overhead; royalties flow from approved products with established markets. Royalty model risks: Innoviva's income depends on GSK's commercial success; if GSK's market share erodes (competition, generic entry, formulary exclusion), Innoviva's royalties decline without Innoviva's ability to control the outcome.

What is the Ellipta respiratory franchise and why is COPD a large market?

The Ellipta is a dry powder inhaler (DPI) device developed through the GSK-Theravance collaboration; once-daily dosing and ease of use were key selling points in the COPD market where many patients are elderly. Ellipta products: Breo Ellipta (fluticasone furoate/vilanterol, ICS+LABA) for asthma and COPD; Anoro Ellipta (umeclidinium/vilanterol, LAMA+LABA) for COPD; Incruse Ellipta (umeclidinium, LAMA) for COPD. COPD market scale: COPD is the third leading cause of death globally; approximately 380 million people have COPD worldwide; in the U.S., approximately 16 million are diagnosed; COPD is a chronic, incurable condition requiring lifelong maintenance therapy; the inhaled therapy market for COPD is $20+ billion annually globally. Ellipta products compete with AstraZeneca's Symbicort and Breztri, Boehringer Ingelheim's Spiriva, and GSK's own older products.

What is the REMS program for sodium oxybate and why is it required?

REMS (Risk Evaluation and Mitigation Strategy) is a program that FDA requires for drugs with serious safety concerns; REMS may include restricted distribution through certified pharmacies, patient and prescriber enrollment, and monitoring requirements. Sodium oxybate is a Schedule III controlled substance; GHB has a history of abuse as a 'date rape drug' — it is a potent CNS depressant that causes sedation, amnesia, and respiratory depression at high doses. REMS requirements: sodium oxybate can only be dispensed through a centralized specialty pharmacy distribution program; prescribers must be certified through the REMS; patients must acknowledge the risks and agree to safeguards; quantities are limited to prevent diversion. Commercial implications: the centralized distribution model means Avadel cannot rely on retail pharmacy networks; REMS administration costs (program management, pharmacy network, patient enrollment) add to commercial operating costs not present in typical drug launches; the controlled substance designation and REMS requirements also create barriers to entry for potential future competitors.

Last updated: August 5, 2026

brimindinvest.com / compare / avdl-vs-invaLIVE

AVDL

Avadel Pharmaceuticals plc · Healthcare - Specialty Pharma (Neuroscience)

N/A

N/A this month

VERSUS

⟷

COMPARE

INVA

Innoviva, Inc. · Healthcare - Royalty and Specialty Pharma

$20.87

-4.35% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

AVDL

0

INVA

0

MIXED SETUP

Comparison scoreboard

MIXED SETUP

AI Score

AVDL N/A

INVA 34.6

1Y Return

AVDL N/A

INVA +13.18%

Fwd P/E

AVDL N/A

INVA 9.44

Target Up.

AVDL N/A

INVA +70.10%

Op. Margin

AVDL N/A

INVA N/A

Metrics last refreshed: 8/5/2026

Quick take

AVDL vs INVA Stock Comparison: AI Score, Valuation, Performance and Upside

AVDL (Avadel Pharmaceuticals) and INVA (Innoviva) are both specialty pharmaceutical companies with distinct business models — Avadel is a commercial-stage company dependent entirely on LUMRYZ's once-nightly sodium oxybate commercial success in narcolepsy against Jazz Pharmaceuticals' established franchise, while Innoviva is a royalty-oriented company collecting passive income from GlaxoSmithKline's Ellipta respiratory franchise with Entasis Therapeutics antibiotic operations as a secondary asset.

AVDL vs INVA is single-product commercial narcolepsy company with genuine once-nightly dosing differentiation (Avadel's LUMRYZ convenience advantage over twice-nightly dosing, oxybate's proven efficacy, and physician switching potential — managing gross-to-net complexity, REMS administration, and single-product revenue risk) versus passive royalty business on GSK's Ellipta respiratory products (Innoviva's capital-light royalty model on approved respiratory products with Entasis antibiotic optionality — navigating GSK commercial dependency and Ellipta patent timelines).

Live analysis · updated 8/5/2026

AVDL and INVA are closely matched — they split the tracked metrics evenly.

Normalized 1Y performance

AVDL

INVA

Not enough data to chart yet.

Recent returns

AVDL

INVA

Analyst price targets & sentiment

AVDL

Price target data unavailable

N/A

INVA · 4 analysts

Price target range

analyst low$18.00
analyst high$46.00
analyst mean$35.50
current price$20.87

+70.1% upside to analyst mean

Who should consider this stock?

AVDL may suit investors who:

→Want exposure to a commercial narcolepsy company with genuine clinical differentiation through once-nightly sodium oxybate addressing a significant patient quality-of-life improvement vs. Jazz's twice-nightly standard
→Believe LUMRYZ's once-nightly dosing advantage will drive meaningful physician switching from established Jazz products despite Jazz's entrenched narcolepsy relationships
→Accept single-product commercial stage binary risk in exchange for potential significant upside if LUMRYZ achieves substantial sodium oxybate market share

INVA may suit investors who:

→Want passive royalty exposure to GSK's established Ellipta respiratory franchise in COPD and asthma without operational pharma execution risk
→Value Innoviva's capital-light royalty model that generates income from GSK's commercial activities without the cost of manufacturing, sales force, or regulatory affairs
→See Entasis's sulbactam/durlobactam approval as providing value optionality in the hospital antibiotic market for drug-resistant Acinetobacter infections on top of the Ellipta royalty baseline

Performance & AI score

Performance & AI score
Metric	AVDL	INVA
AI score	N/A	34.6
AI rank	N/A	#1697
Latest close	N/A	$20.87
1M return	N/A	-4.35%
6M return	N/A	-0.62%
1Y return	N/A	+13.18%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

$10,000 invested — hypothetical growth (dividends reinvested)
Period	AVDL	INVA
1Y ago	N/A	$11.32K (+13.2%) started 2025-08-05
5Y ago	N/A	$13.52K (+35.2%) started 2021-08-05
10Y ago	N/A	$16.43K (+64.3%) started 2016-08-05

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Valuation & upside potential
Metric	AVDL	INVA
Market cap	N/A	$1.54B
Trailing P/E	N/A	3.32
Forward P/E	N/A	9.44
Price/Sales	12.56	3.66
EV/Revenue	N/A	2.98
Analyst target	N/A	$35.50
Target upside	N/A	+70.10%

Growth, profitability & risk

Growth, profitability & risk
Metric	AVDL	INVA
Revenue growth	N/A	10.60%
Earnings growth	N/A	N/A
EPS growth	N/A	N/A
FCF margin	N/A	+25.00%
Operating margin	N/A	N/A
Profit margin	N/A	119.88%
ROIC proxy	N/A	50.72%
Return on equity	N/A	50.72%
Dividend yield	N/A	0.00%
Beta	-0.24	0.34
Debt/equity	N/A	24.70
Current ratio	N/A	21.13
Quick ratio	N/A	19.27

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

AVDL max drawdownN/A

INVA max drawdown20.32%

AVDL max wkly dropN/A

INVA max wkly drop8.46%

5Y risk snapshot

AVDL max drawdownN/A

INVA max drawdown47.01%

AVDL max wkly dropN/A

INVA max wkly drop10.99%

10Y risk snapshot

AVDL max drawdownN/A

INVA max drawdown59.57%

AVDL max wkly dropN/A

INVA max wkly drop32.64%

Performance metrics by period

Performance metrics by period
Period	Metric	AVDL	INVA
1Y	Growth	N/A	+13.18%
	CAGR	N/A	+13.19%
	Sharpe ratio	N/A	0.41
	Max drawdown	N/A	20.32%
	Max daily drop	N/A	4.10%
	Max wkly drop	N/A	8.46%
5Y	Growth	N/A	+35.17%
	CAGR	N/A	+6.21%
	Sharpe ratio	N/A	0.19
	Max drawdown	N/A	47.01%
	Max daily drop	N/A	7.83%
	Max wkly drop	N/A	10.99%
10Y	Growth	N/A	+64.33%
	CAGR	N/A	+5.09%
	Sharpe ratio	N/A	0.18
	Max drawdown	N/A	59.57%
	Max daily drop	N/A	18.00%
	Max wkly drop	N/A	32.64%

Business comparison

Business comparison
Category	AVDL	INVA
Company	Avadel Pharmaceuticals plc	Innoviva, Inc.
Sector	Healthcare - Specialty Pharma (Neuroscience)	Healthcare - Royalty and Specialty Pharma
Industry	N/A	N/A
Core business	Avadel Pharmaceuticals is a commercial-stage specialty pharmaceutical company with LUMRYZ (sodium oxybate extended-release), the first and only once-nightly formulation of sodium oxybate approved for narcolepsy in adults (FDA approved 2023). Sodium oxybate (a form of gamma-hydroxybutyrate, GHB) is the most effective treatment for narcolepsy — it improves all core narcolepsy symptoms including cataplexy, excessive daytime sleepiness, and disrupted nighttime sleep. LUMRYZ's once-nightly dosing is a significant advantage over the twice-nightly dosing of Jazz Pharmaceuticals' sodium oxybate products (Xyrem and Xywav), which require patients to set a middle-of-the-night alarm to take the second dose. Avadel uses a proprietary extended-release technology (Micropump) to achieve once-nightly dosing that provides exposure throughout the night.	Innoviva is a royalty and specialty pharmaceutical company built primarily around its royalty interests in GlaxoSmithKline's Ellipta respiratory product franchise — specifically Breo Ellipta (fluticasone furoate/vilanterol for asthma and COPD), Anoro Ellipta (umeclidinium/vilanterol for COPD), and Incruse Ellipta (umeclidinium for COPD). Innoviva receives royalties from GSK on global net sales of these products. Innoviva also has a majority stake in Entasis Therapeutics, which develops novel antibiotics for drug-resistant bacterial infections. Innoviva's primary value driver is the royalty stream from the Ellipta franchise.
Investor focus	Investors track LUMRYZ's net revenue growth, prescription volume vs. Jazz Pharmaceuticals' Xyrem and Xywav market share, gross-to-net discount management, and cash burn trajectory to profitability.	Investors track the GSK Ellipta franchise's global net sales growth (particularly Breo Ellipta, the largest product), royalty payments received, Entasis Therapeutics' commercial and clinical progress, and Innoviva's cash management and dividend policy.

AVDL strengths

→Once-nightly dosing is a clinically meaningful differentiation vs. twice-nightly Jazz products — waking in the middle of the night to take a second sodium oxybate dose is highly disruptive for narcolepsy patients and caregivers; LUMRYZ's once-nightly convenience is a genuine quality-of-life improvement that supports patient and physician preference
→Sodium oxybate is the most effective treatment for narcolepsy with a long history of clinical use — the oxybate class has been used in narcolepsy for 20+ years; LUMRYZ's active ingredient has an established efficacy and safety profile; physicians are comfortable with the class and the benefits/risk profile is well characterized
→FDA approval with successful REMS program implementation demonstrates regulatory execution — oxybate products have significant abuse potential; successfully implementing the required REMS program and receiving FDA approval demonstrates Avadel's regulatory and commercial capabilities

INVA strengths

→Ellipta respiratory franchise royalties provide stable, non-operational income from GSK's global respiratory business — Innoviva collects royalties without the cost of manufacturing, regulatory affairs, or commercial execution; the royalty model is capital-light
→Royalty model insulates Innoviva from many pharma execution risks — Innoviva does not bear the risk of pipeline failures (Ellipta products are already approved); commercial execution risk falls on GSK
→Entasis Therapeutics provides growth optionality beyond Ellipta royalties — Entasis's sulbactam/durlobactam (Xacduro) received FDA approval in 2023 for Acinetobacter baumannii infections

Risks to watch — AVDL

→Jazz Pharmaceuticals has enormous resources and established relationships in narcolepsy — Jazz has marketed sodium oxybate since 2002 and has 20+ years of narcolepsy specialist relationships; Avadel must convince physicians comfortable with Jazz products to try LUMRYZ
→Gross-to-net discounts and REMS program administration costs are significant — specialty pharma for controlled substances has high administrative costs (REMS program, pharmacy distribution controls) and payer rebate requirements
→Single-product commercial stage company carries concentrated risk — if LUMRYZ commercial uptake disappoints, there is no other product revenue to offset; pipeline development is early stage

Risks to watch — INVA

→Generic competition for Ellipta products threatens the royalty stream — Breo Ellipta and Anoro Ellipta face potential generic competition as patents expire; generic entry would reduce Innoviva's royalties
→GSK's commercial execution determines Innoviva's royalty income — Innoviva's revenue is entirely dependent on how successfully GSK markets Ellipta products globally without Innoviva's direct control
→Entasis commercial execution faces significant challenges in hospital antibiotic market — hospital antibiotics for drug-resistant infections are notoriously difficult commercial opportunities with small patient populations

Frequently asked questions

Narcolepsy is a chronic neurological disorder caused by the loss of hypocretin-producing neurons in the brain — hypocretin regulates sleep-wake transitions; without sufficient hypocretin, the brain loses the ability to maintain stable wakefulness. Symptoms include: Type 1 narcolepsy (with cataplexy): excessive daytime sleepiness, cataplexy (sudden muscle weakness triggered by strong emotions), sleep paralysis, and disrupted nighttime sleep; Type 2 lacks cataplexy but has EDS. Sodium oxybate mechanism: sodium oxybate (GHB, gamma-hydroxybutyrate) consolidates sleep (suppressing abnormal wake intrusions during nighttime sleep) and thereby improves daytime alertness; clinical trials show sodium oxybate reduces cataplexy attacks by 60-85% and significantly improves EDS. Traditional sodium oxybate (Xyrem/Xywav) requires two doses separated by 2.5-4 hours — patients must set an alarm, wake in the night, take the second dose, and return to sleep; LUMRYZ's extended-release formulation delivers both doses in one bedtime administration, eliminating the middle-of-the-night wake-up that is highly disruptive for already sleep-challenged narcolepsy patients.

AI Prediction SignalNext 5 trading days

Members only

AVDL

+2.8%BUY

INVA

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

More comparisons